Catalyst Pharmaceutical
CPRX
CPRX was delisted on the 14th of July, 2026.
62 hedge funds and large institutions have $18M invested in Catalyst Pharmaceutical in 2016 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 13 increasing their positions, 22 reducing their positions, and 27 closing their positions.
15% less funds holding
Funds holding: 73 → 62 (-11)
41% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 27
41% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 22
58% less capital invested
Capital invested by funds: $42.7M → $18M (-$24.7M)
Top Buyers
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$499K |
| 2 |
Millennium Management
New York
|
+$494K |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$263K |
| 4 |
PP
Paloma Partners
Greenwich,
Connecticut
|
+$227K |
| 5 |
DS
DRW Securities
Chicago,
Illinois
|
+$191K |
Top Sellers
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$5.96M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.57M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$1.06M |
| 4 |
State Street
Boston,
Massachusetts
|
-$925K |
| 5 |
JP Morgan Chase
New York
|
-$658K |
CPRX Hedge Fund Activity: Q2 2016 in Review
62 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2016, worth a combined $18M — down 58% from $42.7M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of CPRX and 16 opened new positions — a net loss of 11 holders — while 22 trimmed existing stakes and 13 added.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $499K. The largest seller was Federated Hermes, exiting entirely with an estimated $5.96M sold.
- 62 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2016, down from 73 in Q1 2016.
- Funds reported $18M of Catalyst Pharmaceutical stock for Q2 2016, down 58% quarter-over-quarter.
- 16 funds opened new Catalyst Pharmaceutical positions in Q2 2016 and 27 closed out, a net change of -11 holders.
- The largest Catalyst Pharmaceutical buyer in Q2 2016 was GSA Capital Partners, an estimated $499K added.
- The largest Catalyst Pharmaceutical seller in Q2 2016 was Federated Hermes, an estimated $5.96M sold.
Based on aggregated 13F filings for Q2 2016.